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Abstract
Background: Loss of heterozygosity (LOH) on the long arm of chromosome 16 is one of the
most frequent genetic events in solid tumors. Recently, the AT-motif binding factor 1 (ATBF1)-A gene,
which has been assigned to chromosome 16q22.3-23.1, was identified as a plausible candidate for
tumor suppression in solid tumors due to its functional inhibition of cell proliferation and high
mutation rate in prostate cancer. We previously reported that a reduction in ATBF1-A mRNA levels
correlated with a worse prognosis in breast cancer. However, the mechanisms regulating the
reduction of ATBF1-A mRNA levels (such as mutation, methylation in the promoter region, or
deletion spanning the coding region) have not been fully examined. In addition, few studies have
analyzed LOH status at the ATBF1-A locus, located in the 16q22 minimal region.
Methods: Profiles of ATBF1-A mRNA levels that we previously reported for 127 cases were used.
In this study, breast cancer specimens as well as autologous blood samples were screened for LOH
using 6 polymorphic microsatellite markers spanning chromosome band 16q22. For mutational
analysis, we selected 12 cases and analyzed selected spots in the ATBF1-A coding region at which
mutations have been frequently reported in prostate cancer.
Results:  Forty-three cases that yielded clear profiles of LOH status at both D16S3106 and
D16S3018 microsatellites, nearest to the location of the ATBF1-A  gene, were regarded as
informative and were classified into two groups: LOH (22 cases) and retention of heterozygosity
(21 cases). Comparative assessment of the ATBF1-A mRNA levels according to LOH status at the
ATBF1-A  locus demonstrated no relationship between them. In the 12 cases screened for
mutational analysis, there were no somatic mutations with amino acid substitution or frameshift;
however, two germ line alterations with possible polymorphisms were observed.
Conclusion: These findings imply that ATBF1-A mRNA levels are regulated at the transcriptional
stage, but not by genetic mechanisms, deletions (LOH), or mutations.
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Background
Previous studies, including ours, have shown that loss of
heterozygosity (LOH) on the long arm of chromosome 16
is one of the most frequent genetic events in breast, gastric
and prostate cancers, implying the presence of one or
more tumor suppressor genes (TSGs) at this location [1-
7]. In breast cancer, the gene encoding E-cadherin  at
16q22.1 was identified as a TSG, but only in the histolog-
ical subgroup of lobular carcinoma [8]. Recently, the AT-
motif binding factor 1 (ATBF1)-A gene (GenBank: L32832),
which has been assigned to chromosome 16q22.3-23.1
[9], was identified as a reasonable candidate for tumor
suppressor activity in solid tumors, based on its func-
tional inhibition of cell proliferation and high rate of
mutations in prostate cancer [10].
ATBF1-A was originally identified as a negative transcrip-
tional factor for the alpha-fetoprotein (AFP) gene through
binding with the AT-rich motif in the AFP enhancer ele-
ment I [11,12]. In gastric cancer, absence of ATBF1-A is a
distinct feature of AFP-producing cancer cells, which are
characterized by a high malignant potential [7,13]. More-
over, ATBF1-A negatively regulates the c-Myb oncoprotein
[14] and transactivates the cell cycle inhibitor CDKN1A
[15]. Therefore, the ATBF1-A gene is considered to be a
good TSG candidate in solid tumors.
Previously, we reported that reduced ATBF1-A mRNA lev-
els in tumors correlated with axillary lymph node metas-
tasis and estrogen receptor (ER)-α negative status in breast
cancer, and with a worse prognosis [16]. Sun et al. con-
firmed the presence of reduced ATBF1-A mRNA levels in
breast cancer cell lines [17]. However, the reduced ATBF1-
A mRNA expression was attributed neither to promoter
methylations nor to frequent somatic mutations [17].
Therefore, the authors concluded that ATBF1-A plays a
role in breast cancer through transcriptional down-regula-
tion rather than promoter methylation or mutations.
In addition to promoter methylations or mutations, LOH
resulting from a deletion spanning one or more genes is
one of the mechanisms by which the function of genes is
lost. However, there are no papers in which has been
reported the associations between LOH at the ATBF1-A
locus [10] in the 16q22 minimal region and AFBF1-A
mRNA levels, or between LOH at this locus and the clin-
icopathological factors in breast cancer. We performed
LOH analysis at the 16q22 minimal region and muta-
tional analysis focusing on specific loci in the ATBF1-A
gene, which have been reported previously in prostate
cancer[10]. Our analysis shows that ATBF1-A mRNA lev-
els are not regulated by genetic machinery, LOH, or muta-
tions. These findings could support the view that the
ATBF1-A gene plays a role in breast cancer through tran-
scriptional down-regulation rather than through LOH
and mutations.
Methods
Patients and samples
Specimens of primary breast carcinomas were obtained by
surgical excision from 127 female patients who received
treatment at the Department of Breast and Endocrine Sur-
gery, Nagoya City University Hospital, Nagoya, Japan,
between 1993 and 2000. All the patients in the present
study had ATBF1-A mRNA profiles, as reported previously
[16]. Informed consent was obtained from all the patients
before surgery. The ethics committee of Nagoya City Uni-
versity Graduate School of Medicine, Nagoya, approved
the study protocol. Of the 127 tumors obtained from
these patients, 109 were infiltrating ductal carcinomas
and 14 were special type carcinomas, including 8 infiltrat-
ing lobular carcinomas. The remaining 4 patients had
noninvasive carcinomas. The median age of the patients
was 58 years (range, 34–88 years). The patients' tumors
were classified according to the staging system of Interna-
tional Union Against Cancer as follows: 4 cases were clas-
sified as stage 0, 29 as stage I, 78 as stage II, 12 as stage III,
and 4 as stage IV. Patients were graded histopathologically
according to the modified Bloom and Richardson method
proposed by Elston and Ellis [18]. Blood samples were
also taken from each patient. Genomic DNA from the
breast cancer specimens and blood samples were extracted
by standard techniques. Breast cancer specimens were ver-
ified not to contaminate normal cells at 10% or more of
each sample on the hematoxylin and eosin stained slides
as previously described[19].
Microsatellite markers and LOH analysis
The breast cancer specimens as well as the autologous
blood samples were screened using 6 polymorphic micro-
satellite markers spanning chromosome band 16q22 con-
taining the ATBF1-A gene. The order of microsatellite loci
was assessed as reported by Sun et al[10] and with refer-
ence to NCBI [20]. Details of the investigated markers and
their chromosomal locations are provided in Table 1.
Assays were performed by fluorescent-labeled PCR ampli-
fication using fluorescent dye-labeled forward primer and
unlabeled reverse primer (Applied Biosystems). PCR was
performed in 15-μL reaction volumes containing 120 ng
of genomic DNA, 9 μL of ABI Prism True Allele PCR
Premix (Applied Biosystems), 5 pmol of fluorescent dye-
labeled forward primer, and 5 pmol of unlabeled reverse
primer under the following cycling conditions recom-
mended by manufacture's instructions: denaturation at
95°C for 12 min; 10 cycles at 94°C for 15 s, 55°C for 15
s, and 72°C for 30 s; 20 cycles at 89°C for 15 s, 55°C for
15 s, and 72°C for 30 s; and a final extension at 72°C for
10 min. Each 1-μL sample of the resulting PCR products
was diluted with 20 μL of H2O, and a 1.0-μL aliquot ofBMC Cancer 2008, 8:262 http://www.biomedcentral.com/1471-2407/8/262
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each diluted fluorescent-labeled PCR product was com-
bined with 12 μL of formamide and 0.5 μL of GeneScan
500 LIZ size standard (Applied Biosystems). Capillary
electrophoresis was then performed using an ABI 310
DNA Analyzer, and the results were analyzed using Gen-
eMapper software (Applied Biosystems). Representative
results are shown in Figure 1. Allelic loss at each microsat-
ellite locus was considered to be present in tumor sam-
ples' DNA when there was at least a 65% peak reduction
at one of a pair peak compared with the corresponding
peak of normal DNA.
Gene alterationanalysis of ATBF1-A gene
With intent to analyze ATBF1-A mutations, we selected all
the mutational spots in exon 9 and the most frequent
deletion spot in exon 10 reported in prostate cancer
because > 80% of the mutations reported in the paper
were located in these spots (Table 2) [10]. Genomic DNA
was amplified by PCR using the amplifying and sequenc-
ing primers for these spots on the ATBF1-A gene, as listed
in Table 2. For mutation identification, the samples were
subsequently analyzed using an ABI PRISM 310 Genetic
Analyzer (Applied Biosystems). The sequencings from 50
Table 1: Characteristics of polymorphic loci at the 16q22 minimal region
No. Locus name Product size (bp) Genetic map (bp) Genetic map (cM) Microsatellite status
1 D16S3031 258–280 64338900–64339200 85.34 Heterozygous
2 D16S752 101–129 69892700–69892800 87.06 Heterozygous
3 D16S3106 166–206 70745300–70745500 88.18 Heterozygous
4 RH69880 149 71553100–71553200 ND Homozygous
5 D16S2859 186 71675300–71675400 ND Homozygous
6 D16S3018 244–270 72730200–72730500 90.65 Heterozygous
7 D16S3049 233–255 77478800–77479100 97.03 Heterozygous
8 D16S504 149 77723500–77723600 101.23 Heterozygous
The genetic maps were cited from NCBI Map Viewer http://www.ncbi.nlm.nih.gov/mapview/. ND, not described.
Representative examples of microsatellite analysis for D16S3018 in breast cancer patients with paired tumor-blood Figure 1
Representative examples of microsatellite analysis for D16S3018 in breast cancer patients with paired tumor-
blood samples. (a) Loss of heterozygosity at D16S3018. The arrow indicates the allele loss. (b) Retention of heterozygosity. 
(c) Uninformative sample due to the homozygosity at D16S3018. Each peak has a box that provides the fragment size and peak 
height (upper and lower labels, respectively).
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to 250 bp, counting from the starting point, were regarded
as the region of interest.
Immunohistochemical staining of ER-α, progesterone 
receptor, and human epidermal growth factor receptor 2
Immunostaining of ER-α, progesterone receptor (PR), and
human epidermal growth factor receptor 2 (HER2) was
performed, as described previously [21]. Primary antibod-
ies included monoclonal mouse antihuman estrogen
receptor antibody (1D5; DAKO, Glostrup, Denmark) at
1:100 dilution for ER-α, antihuman PR antibody (PR636;
DAKO, Kyoto, Japan) at 1:100 dilution for PR, and rabbit
antihuman c-erbB2 oncoprotein antibody (DAKO) at
1:200 dilution for HER2. A Streptavidin-biotin system
(SAB-PO kit; Nichirei, Tokyo, Japan) was used for the
detection of ER-α, PR, and HER2 according to the manu-
facturer's instructions. The expression of ER-α and PR was
scored by assigning a proportion score and an intensity
score according to Allred's procedure [22]. Immunohisto-
chemical scoring of HER2 was accomplished as described
previously [21].
Statistical analysis
The nonparametric Mann-Whitney U-test was used for
statistical analysis of the association between LOH status
at the ATBF1-A locus and ATBF1-A mRNA levels. The χ2
test was used to compare LOH status at the ATBF1-A locus
with the clinicopathological characteristics. All values
with P < 0.05 were considered statistically significant.
Results
Loss of heterozygosity at chromosome band 16q22
Initially, we performed LOH analysis using microsatellite
markers spanning 16q22. Sun et al. narrowed the region
of deletion at 16q22 in prostate cancer to 861 kb contain-
ing the ATBF1-A gene[10]. We used microsatellite markers
either in the narrowed 861-kb region or close to the nar-
rowed region spanning 16q22 (Table 1). However, both
microsatellite markers in the narrowed region, RH69880
and D16S2859, were homozygous (uninformative).
Thereafter, we performed LOH mapping using 6 other
microsatellite markers. Next, to determine the most rea-
sonable set of microsatellite markers reflecting LOH status
at the ATBF1-A locus, we tested various kinds of microsat-
ellite marker sets from among the 6 microsatellite markers
(data not shown). Ultimately, we defined LOH status at
the ATBF1-A locus as follows: LOH was identified when
the microsatellite markers at both D16S3106 and
D16S3018 showed LOH; retention of heterozygosity
(ROH), when both D16S3106 and D16S3018 showed
ROH; not determined (ND), when there was discrepancy
in LOH status between D16S3106 and D16S3018,
because ATBF1-A is located between these markers, LOH
status at ATBF1-A  is not rigorously determined in this
case; and uninformative (UI), when there was constitu-
tional homozygosity or an uninterpretable result for at
least one of the two microsatellites. The partial results (all
cases except UI) of LOH analysis at the 16q22 minimal
region are shown in Figure 2. Constitutional heterozygous
(informative) status in both D16S3106 and D16S3018
was observed in 52 cases (44.4%). Of the 52 cases, clear
LOH was seen in 22 cases (42.3%), ROH in 21 (40.4%),
and ND in 9 (17.3%). Subsequently, we analyzed the rela-
tionship between LOH status at the ATBF1-A locus and
ATBF1-A mRNA expression levels as well as the clinico-
pathological factors in a study cohort consisting of these
43 informative cases, classifying them into LOH (n = 22)
and ROH (n = 21) groups.
Table 2: Paired primers used to amplify the specific sequence of ATBF1-A, including the partial mutation loci previously reported in 
prostate cancer
Primer sequence (5'→3')
Exon Mutation 
no.
Nucleotide* Amino acid Forward Reverse Product 
size (bp)
9 1 (5556–5559) del Frameshift AGCAACCGGTCAGCCAGAAC GGTGGCATCCCTACACTCTCAG 336
2 5602C→T No change
3 (5891–5896) del CTCCAAGCTCTAACTTACTAAGCCAA AGTTGCAGCAGGGTCTCAGTT 349
4 5897insCAA Gln1741ins
5 6350delAG Frameshift AGCCAGCACCCCGAAAAGA CTTGCCGCAGGAGTCACAC 360
6 6447delG Frameshift
7 7154C→T R2160W CACCGGCCCAGCCATCAGT AACCCGGACTTGTCTGCCATCT 322
8 8364A→G Gln2564Arg TCAACTCCTCAACAGCTCGCAA GCTTGCACTGGCCTTTTCCTC 333
9 8919C→T A2749V CGCAGGCCCACAGGAGA CAAAGTCTTCAATCCCTTCCACC 321
10 9380A→G S2903G AACTCTTCTAAGCCCTTCCTCCAT CACTGTAGTCCACTGTACCTTCATTG 356
11 9434G→A A2921T CCGAGCTTTTATAGCAAGGAATATG ACTTGGACTTCTTTTCTTTTGCCC 322
10 12 (10814–10834)del 7 amino acid loss TCCTTACTTTGTACCAGGCTTTTCTC TCTTCTGGTTTGGGGGATTCTTTG 345
13 (10814–10837)del 8 amino acid loss
14 (10826–10846)del 7 amino acid loss
*ATBF1 mutations previously reported in prostate cancer by Sun et al. [10]BMC Cancer 2008, 8:262 http://www.biomedcentral.com/1471-2407/8/262
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Comparison of ATBF1 mRNA expression according to 
LOH status at the ATBF1-A locus
In a previous study, we demonstrated that the ATBF-A
mRNA expression level was a significant prognostic
marker in breast cancer [16]. However, the factors regulat-
ing the transcriptional level of the ATBF1-A gene are still
not clear. Using ATBF1-A mRNA data, as reported previ-
ously [16], we investigated whether LOH status at the
ATBF1-A locus regulates the transcriptional level of the
ATBF1-A gene. Figure 3 shows a quantitative assessment
of ATBF1-A mRNA expression according to LOH status at
the ATBF1-A locus and demonstrates that there was no
relationship between them. This finding indicates that
another mechanism is involved in regulating the tran-
scriptional level of the ATBF1-A gene.
ATBF1-A nucleotide alterations in breast cancer
We next performed mutational analysis of the ATBF1-A
gene to inspect whether ATBF1-A mRNA expression levels
could be related with mutations succeeding to the insta-
bilities of their transcripts. We selected all the mutational
spots located in exon 9 and the most frequent deletion
spot in exon 10 (Table 2), because > 80% of the mutations
in the coding region of ATBF1-A gene reported in prostate
cancer occurred in these locations. Twelve patients with
tumors that did not demonstrate LOH at the ATBF1-A
locus but with lower ATBF1-A  mRNA expression were
chosen as study subjects for mutational analysis. Overall,
five sequence alterations, including both mutations and
polymorphism, were found in the abovementioned spots
in the 12 samples from these patients. Two patients had a
somatic (blood sample not matched) 5602C > T mutation
in one allele that did not involve amino acid substitution
(i.e., synonym mutations). On the other hand, one
patient had a 5602C > T blood-sample matched alteration
in one allele that was reported on the dbSNP database
[23]. We therefore regarded it as a single nucleotide poly-
morphism (SNP), as reported by Sun et al[17]. Both the
remaining samples demonstrated a germ line alteration
(blood-sample matched) in one allele. One of them,
8387A > G, caused a substitution of methionine for valine
at codon 2572. The other alteration was a deletion
(10799–10804) without frameshift. Although both gene
alterations were not reported in the NCBI dbSNP and
JSNP databases [24], we could not immediately rule out
the possibility that these alterations were benign poly-
morphisms.
Relationship between LOH status of the ATBF1-A locus 
and clinicopathological factors
As the reduced ATBF1-A mRNA expression levels corre-
lated with unfavorable characteristics of tumors, ER-α-
negative and lymph node metastasis, in our previous
study[16], we wondered whether LOH status at ATBF1-A
locus were related with clinicopathological factors as well.
The results of this analysis are shown in Table 3. LOH at
the ATBF1-A locus correlated with positivity of PR (P =
0.013) and negativity of HER2 (P = 0.024) status. Patients
with ER-α-positive tumors were more likely to demon-
strate LOH at the ATBF1-A locus than those with ER-α-
negative tumors; however, the difference was not signifi-
cant. Furthermore, the patients with LOH at the ATBF1-A
locus more often had axillary lymph node involvement
than those without LOH (P = 0.084). No relationship was
observed between LOH at the ATBF1-A locus and other
clinicopathological factors, such as age, tumor size, and
histological grade.
Discussion
Using polymorphic microsatellite markers spanning chro-
mosome 16q22, we performed fluorescent-labeled PCR
amplification and capillary electrophoresis to investigate
LOH status at the 16q22 minimal region in paired speci-
mens of blood and primary breast tumors from 127
patients. We assessed the relationship between LOH sta-
tus at the ATBF1-A locus and mRNA levels of ATBF1-A, as
well as the clinicopathological factors in breast cancer.
Quantitative assessment of ATBF1-A  mRNA expression
according to LOH status at the ATBF1-A locus demon-
strated no relationship between these factors. This finding
completely consists with the result repoted by Kim et al.,
studied in hepatocellular carcinoma (HCC)[25]. We
therefore concluded that a mechanism other than LOH
was involved in regulating the transcriptional level of the
ATBF1-A gene in breast cancer as like in HCC.
Accordingly, we screened mutations of the specific loci in
the ATBF1-A gene that have previously been reported in
prostate cancer [10]. The 12 tumors investigated for muta-
tions had been predicted to have a higher frequency of
gene alterations in the ATBF1-A gene, because they dem-
onstrated lower ATBF1-A mRNA levels but showed ROH
at the ATBF1-A locus (data not shown). In the mutational
analyses, although none of the 12 samples studied
showed somatic mutations with substitution of amino
acids or frameshift, two germ line gene alterations were
recorded. One of these alterations predicted a substitution
of methionine for valine at codon 2572. This alteration
also reported in gastric cancer as a somatic mutation at
one allele, while the other allele had lost[7]. Although the
gene alteration was not reported in the NCBI SNP and
JSNP databases, pathogenic significance of the gene alter-
ation was also not verified by functional assay. The
remaining gene alteration produced a 6-nucleotide dele-
tion without frameshift in glutamic acid rich domain in
exon10. Although the 3 – 24 nucleotides deletions are
prevalent in various kind of tumors[6,7,10,26], its
pathogeny is controversial among those tumors. In pros-
tate cancer, Xu et. reported the deletions in germline and
its relevance with the susceptibility to prostate cancer[26].BMC Cancer 2008, 8:262 http://www.biomedcentral.com/1471-2407/8/262
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Loss of heterozygosity (LOH) mapping of the 16q22 minimal region in breast cancer Figure 2
Loss of heterozygosity (LOH) mapping of the 16q22 minimal region in breast cancer. All cases except those that 
were uninformative are shown. The LOH status at the ATBF1-A gene locus was categorized as follows: LOH, indicating that 
LOH status at both D16S3106 and D16S3018 showed LOH; retention of heterozygosity (ROH), indicating that both 
D16S3106 and D16S3018 showed ROH; not determined, indicating that there was a discrepancy in LOH status between 
D16S3106 and D16S3018.
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Contrast to that, in breast cancer, Cleton-Jansen et al.
reported no association between these germline deletions
and suscetability to breast cancer[6]. This indicate that
these germline deletions has different impacts in the sus-
cetabilities to these tumors. As in the present study, the
deletion was also germline, they might be benign poly-
morphisms regarding with the susceptibility to breast can-
cer.
A larger case-control study compared between cancer
patients and healthy individuals and functional analysis
in each gene alteration should be performed to reveal
their pathogenic significances in tumorigenesis. As, conse-
quently, somatic mutations with substitution of amino
acids or frameshift were not seen in these samples, we
concluded that ATBF1-A mRNA levels may be regulated at
the transcriptional stage, but are not regulated by genetic
mechanisms, deletions (LOH), or mutations in breast
cancer. Infrequent somatic mutations in ATBF1-A  gene
have previously been reported, except for prostate cancer.
The frequencies were 8.6% in gastric cancer[7], 0% in
HCC[25], 0% in breast cancer[6]. In addition, Sun et al.
and Kim et al. reported infrequent methylation at ATBF1
gene promoter in breast cancer and HCC, respec-
tively[17,25]. Based on these reports, we speculate that
the methylations at ATBF1-A gene are also not attributed
to the downregulation of ATBF1-A transcripts, though we
did not performed the methylation analysis.
Recently, posttranscriptional mRNA repression associated
with microRNA (miRNA) have been discussed as an alter-
native mechanism of mRNA modulation at the posttran-
scriptional level in mammals as well as metazoa [27].
According to the prevailing model, posttranscriptional
repression by miRNA is determined by the complementa-
rity to the miRNA of the target mRNA[27]. Therefore, we
may speculate that posttranscriptional cleavage of mRNA
by miRNA-associated machinery is the molecular mecha-
nism of ATBF1-A mRNA regulation. This may explain why
there is a discrepancy between LOH status at ATBF1-A
locus and ATBF1-A mRNA levels.
LOH status at the ATBF1-A locus significantly correlated
with positivity of PR (P = 0.013) and negativity of HER2
(P  = 0.024) status. Similar results were previously
reported by Wang [28], who found that 16q23-24 genetic
loss significantly correlated with ER-α positivity and
HER2 negativity. These biological features, hormonal
receptor positivity, and HER2 negativity, are reminiscent
of the "luminal-type" tumors described by Perou et al.
[29]. Based on the study by Wang [28] and the present
study, a target gene at the narrowed locus spanning from
16q22 to 16q24 may determine the biological features of
the luminal-type. Recent cytogenetic approaches, such as
comparative genomic hybridization[30], may help reveal
the new target gene at this locus in such cohorts.
Conclusion
Using polymorphic microsatellite markers spanning chro-
mosome band 16q22, we defined LOH status at the
ATBF1-A  locus and performed comparative analysis
between LOH and ROH groups. However, we did not find
a significant correlation between LOH status at the
ATBF1-A locus and ATBF1-A mRNA levels. Furthermore,
we found no somatic mutations with amino acid substitu-
tion in 12 tumor samples from selected patients who were
predicted to have a higher frequency of gene alterations,
although two germ line alterations with the possibility of
polymorphism were noted. We therefore conclude that
ATBF1-A mRNA levels may be regulated at the transcrip-
tional stage.
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